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Using ex vivo antigen-specific T-cell analysis, we found that symptomatic cytomegalovirus recrudescence in
transplant recipients was coincident with reduced expression of gamma interferon (IFN-) by virus-specific
CD8 T cells and an up-regulation of CD38 expression on these T cells, although there was no significant
change in the absolute number of virus-specific cells (as assessed by major histocompatibility complex-peptide
multimers). In contrast, HLA class I-matched transplant patients with asymptomatic viral recrudescence
showed increased expansion of antigen-specific T cells and highly stable IFN- expression by epitope-specific
T cells. These studies suggest that a strong functional T-cell response plays a crucial role in defining the
clinical outcome of acute viral recrudescence.
The clinical presentation of acute latent viral infections and
its interaction with host T-cell responses have recently been
investigated in order to understand the dynamics of immune
regulation and to develop better therapeutic strategies (5, 9,
10, 20). Previous studies have proposed a role for a number of
potential factors, such as viral load and cytokine dysregulation,
in controlling the symptoms of acute viral infection (1, 17). It
is entirely feasible that the dynamics of emergence of the
virus-specific T-cell response during the early stages of viral
recrudescence may delimitate the patterns of clinical symp-
toms in different individuals (11, 13, 16). Indeed, massive ex-
pansion of CD8 T cells specific for Epstein-Barr virus latent
and lytic antigens, which is often a feature of acute Epstein-
Barr virus infection, suggests that these T-cell responses are
recruited to control the active viral infection (2). However,
understanding the biological significance and the longitudinal
dynamics of these T cells during acute viral infections in hu-
mans is often difficult and is complicated by the nature of
immune responses in naturally outbred individual patients. We
have addressed some of these limitations by analyzing the
dynamics of T-cell responses to a panel of CD8 T-cell
epitopes in a group of HLA class I-matched unrelated human
subjects undergoing acute human cytomegalovirus (HCMV)
infection with contrasting clinical symptoms. We studied three
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TABLE 1. List of HLA class I-restricted HCMV epitopes used in this study
Epitope sequence (code) HLArestriction
Antigen Assay used:
Name Expression kinetics ELISPOT MHC-peptidetetramer
YSEHPTFTSQL (YSE) A1 pp65 Late/structural X
RPHERNGFTVL (RPH) B7 pp65 Late/structural X
NLVPMVATV (NLV) A2 pp65 Late/structural X X
VTEHDTLLY (VTE) A1 pp50 Late/structural X X
TPRVTGGAM (TPR) B7 pp65 Late/structural X X
VLEETSVML (VLE) A2 IE-1 Immediate-early X
ELRRKMMYM (ELR) B8 IE-1 Immediate-early X












broad groups of transplant patients: (i) individuals with asymp-
tomatic viral recrudescence, (ii) individuals with symptomatic
viral recrudescence, and (iii) individuals with no evidence of
viral recrudescence. In each of these groups of patients we
longitudinally analyzed CD8 T-cell responses using ex vivo
ELISPOT assays and major histocompatibility complex
(MHC)-peptide multimer analysis. In addition, we also as-
sessed the viral load in these individuals to determine whether
there was any correlation with T-cell dynamics and/or clinical
symptoms.
Peripheral blood samples from a cohort of 15 HLA class
I-matched solid-organ transplant (SOT) patients (renal or
heart and/or lung) were collected into EDTA collection tubes.
These blood samples were collected at multiple time points
(see Fig. 1), cryopreserved, and used for T-cell assays and viral
load analysis. All blood samples were collected following in-
formed consent, and the study was approved by the relevant
human ethics committees. Clinical diagnosis of symptomatic
viral recrudescence was based on laboratory diagnosis (pp65
antigenemia; 10 positive cells/106 peripheral blood mononu-
clear cells [PBMC]) and previously published clinical criteria
outlined by the American Society of Transplantation (8). Pa-
FIG. 1. Longitudinal functional analysis of HCMV-specific T cells in HLA class I-matched SOT recipients using IFN- ELISPOT assays and
peptide epitopes from HCMV antigens (Table 1). Data from an individual recipient are presented in each panel. Data from individuals with no
evidence of viral recrudescence are presented in panels A to E, those from individuals with asymptomatic recrudescence are presented in panels
F to J, and those from individuals with symptomatic recrudescence are presented in panels K to O. Data presented in panels A to E, K, L, and
N are based on SOT patients who received heart and/or lung transplants, while data in panels F to J, M, and O are based on renal transplant
recipients. Gray-shaded areas in panels K to O indicate the time period when clinically active HCMV disease was diagnosed and the patient was
being treated with antiviral medication (Table 2). Patients B, D, and E received antiviral prophylaxis based on oral ganciclovir. The results are
expressed as spot-forming cells (SFC) per 106 CD3/CD8 T cells. Also shown in panels F to O is the HCMV load in peripheral blood of these
patients as HCMV copies/106 PBMC. Blood sample collection time points (weeks) for each of the donors are indicated on the x axis.











tients with symptomatic HCMV disease were treated with oral
and intravenous ganciclovir (the exact period of HCMV dis-
ease and treatment is indicated in Fig. 1 as a shaded area) with
the exception of patient N, who received cidofovir. Patient L
also received foscarnet and valganciclovir. The transplant im-
munosuppressive regimens have been outlined elsewhere (14).
Briefly, these patients received cyclosporine, mycophenolate
mofetil, and prednisolone.
In the first set of studies, we longitudinally analyzed the
HCMV-specific T-cell responses using ELISPOT assays and
MHC-peptide pentamer/tetramer staining in these transplant
patients as described previously (3, 4). For these assays,
HCMV epitopes restricted through various HLA class I alleles
(HLA-A1, HLA-A2, HLA-B7, and HLA-B8) were used (Table
1). Data from each of these SOT recipients are presented in
Fig. 1A to O. Longitudinal analysis of immune responses
clearly illustrated that those SOT patients who either showed
no evidence of viral recrudescence (Fig. 1A to E) or showed
asymptomatic viral recrudescence (Fig. 1F to J) maintained a
stable virus-specific gamma interferon (IFN-) expression by
CD8 T cells throughout the follow-up period. These re-
sponses were towards epitopes derived from both structural
and/or IE-1 antigens. In contrast, HLA-matched SOT recipi-
ents who were diagnosed with symptomatic viral recrudescence
(Fig. 1K to O; Table 2) showed significant fluctuations of their
virus-specific IFN- expression by CD8 T cells. These fluctu-
ations ranged from a 3- to 120,000-fold reduction in the virus-
specific CD8 T-cell responses. One of the interesting aspects
of this longitudinal analysis was that patients with symptomatic
viral recrudescence showed reduced IFN- expression (5-
fold reduction) by virus-specific CD8 T cells in70% of their
blood samples, while 10% of the blood samples from SOT
recipients with no viral recrudescence or with asymptomatic
viral recrudescence showed reduced IFN- expression by virus-
specific CD8 T cells. Furthermore, T-cell responses towards
multiple epitopes showed a contemporaneous pattern of fluc-
tuation which is consistent with our previous findings for
healthy virus carriers (3). Most importantly, the reduction in
the IFN- expression by antigen-specific T cells in four of the
five symptomatic recipients preceded the clinical diagnosis of
active disease. It is important to mention here that the viral
load in asymptomatic or symptomatic recipients showed no
correlation with either IFN- expression by HCMV-specific T
cells or clinical symptoms. Taken together, these analyses
strongly suggest that a stable antigen-specific CD8 T-cell re-
sponse is crucial to prevent symptomatic clinical syndromes
following latent viral recrudescence.
To determine whether the reduced IFN- expression by
virus-specific T cells in individuals with symptomatic viral re-
crudescence was due to the loss of HCMV-specific T cells,
PBMC from all SOT recipients were stained with MHC-pep-
tide tetramers/pentamers and anti-CD8 antibody (Fig. 2A).
Data presented in Fig. 2B show that although there was very
little difference in the overall numbers of HCMV-specific T
cells between SOT recipients who showed no viral recrudes-
cence and those who showed symptomatic recrudescence, a
significant increase in the number of HCMV-specific T cells
was observed in individuals with asymptomatic recrudescence.
We hypothesize that this increase in the HCMV-specific T cells
in these individuals is not unexpected, as the viral recrudes-
cence would provide increased stimulation to these cells, re-
sulting in their expansion, and thus provide protection from
clinical disease. It is highly likely that in addition to the re-
duced IFN- expression, the lack of expansion of HCMV-
specific T cells in individuals with symptomatic recrudescence
may also contribute towards the development of clinical dis-
ease. Furthermore, we also observed a significant increase in
the expression of CD38 on the HCMV-specific CD8 T cells in
SOT recipients with symptomatic viral recrudescence com-
pared to recipients who either showed no viral recrudescence
or showed asymptomatic recrudescence (Fig. 2C). No signifi-
cant difference in the expression of CD62L or CD27 on
HCMV-specific CD8 T cells was observed during or after
antiviral prophylaxis (data not shown). Previous studies of hu-
man immunodeficiency virus-infected individuals have shown
that increased expression of CD38 on CD8 T cells is coinci-
dent with chronic human immunodeficiency virus disease pro-
gression to AIDS (12, 15).
In conclusion, this study is the first to demonstrate directly
that a broadly directed CD8 T-cell response with strong func-
tional activity was coincident with the protection from symp-
tomatic viral recrudescence. In addition, we have also shown
that terminal differentiation/exhaustion of antigen-specific T
cells (as indicated by the increased CD38 expression) may
contribute towards the development of clinical symptoms fol-
lowing viral recrudescence. These conclusions are strongly sup-
TABLE 2. Clinical syndrome in active HCMV disease
Patient codea Clinical syndrome Antiviral therapyb
K (D/R) Systemic HCMV infection without defined end organ
involvement
Treatment with ganciclovir (i.v., 400 mg b.i.d.) followed by
oral ganciclovir (1,000 mg t.i.d.)
L (D/R) Clinical disease with very high viral load and antigenemia Treatment with ganciclovir (i.v., 400 mg b.i.d., followed by
valganciclovir at 450 mg b.i.d.); also treatment with a
combination of foscarnet (4 g), i.v. ganciclovir (460 mg),
and CMV hyperimmunoglobulin
M (D/R) Systemic HCMV infection with gastric involvement Treatment with ganciclovir (i.v., 160 mg b.i.d.) followed by
oral ganciclovir (1,000 mg t.i.d.)
N (D/R) HCMV syndrome with end organ disease (liver, pancreas,
brain, and gut)
Treatment with cidofovir (200 mg weekly)
O (D/R) HCMV syndrome without defined end organ involvement Treatment with ganciclovir (i.v., 325 mg b.i.d.) followed by
oral ganciclovir (1,000 mg t.i.d.)
a Patient code refers to the panels in Fig. 1.
b Abbreviations: i.v., intravenous(ly); b.i.d., twice daily; t.i.d., three times daily; D, donor; R, recipient.











ported by previous studies of other viral infections which have
shown that the breadth of the cytotoxic T-lymphocyte response
may be important in preventing viral pathogenesis (1, 18).
Another important implication of this study relates to the
potential use of T-cell functional analysis as a diagnostic tool
for identifying the levels of virus-specific T-cell responses
which would predict the increased or decreased risk of symp-
tomatic HCMV recrudescence (6, 7, 19). The diagnostic ap-
plication of this technology will require an extended analysis of
a larger cohort of transplant patients in various clinical
settings to determine if the protection from HCMV disease
in transplant patients is dependent on T-cell responses di-
rected against a broad range of antigens rather than any
single antigen.
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